Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 6, 2001, Pages 1654-1659

  Coyle, Elizabeth A ^a,b   Kaatz, Glenn W ^b,c,d   Ryba, Michael J ^a,b,c,e  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b WSU   (United States)

^c Henry Ford Health System Division of Infectious Diseases   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e Department of Pharmacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MICROBIAL; HALF-LIFE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0035019811     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.6.1654-1659.2001     Document Type: Article

References (42)

1. Andes, D. R., and W. A. Craig. 1998. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin. Infect. Dis. 27:47-50.
2. Appelbaum, P. C. 1992. Antimicrobial resistance in Streptococcus pneumonia: an overview. Clin. Infect. Dis. 15:77-83.
3. Barry, A. L., P. C. Fuchs, and S. D. Brown. 1996. In vitro activities of five fluoroquinolone compounds against strains of Streptococcus pneumoniae with resistance to other antimicrobial agents. Antimicrob. Agents Chemother. 40:2431-2433.
4. Barry, A. L., S. D. Brown, and P. C. Fuchs. 1999. Fluoroquinolone resistance among recent clinical isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. 43:428-429.
5. Bartlett, J. G., R. F. Breiman, L. A. Mandell, and T. M. File, Jr. 1998. Community-acquired pneumonia in adults: guidelines for management. Clin. Infect. Dis. 26:811-838.
6. Bédos, J.-P., V. Rieux, J. Bauchet, M. Muffat-Joly, C. Carbon, and E. Azoulay-Dupuis. 1998. Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumuniae in a mouse pneumonia model. Antimicrob. Agents Chemother. 42:862-867.
7. Beyer, R., E. Pestova, J. J. Millichap, V. Stosor, G. A. Noskin, and L. R. Peterson. 2000. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob. Agents Chemother. 44:798-801.
8. Brueggemann, A. B., K. C. Kugler, and G. V. Doern. 1997. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoruquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 41:1594-1597.
9. Cappelletty, D. M., and M. J. Rybak. 1996. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model. Antimicrob. Agents Chemother. 40:1148-1152.
10. Chen, D. K., A. McGeer, J. C. De Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-239.
11. Cormican, M. G., and R. N. Jones. 1995. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria. J. Antimicrob. Chemother. 36:431-434.
12. Doern, G. V., A. Brueggemann, H. P. Holley, Jr., and A. M. Rauch. 1996. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40:1208-1213.
13. Ednie, L. M., M. R. Jacobs, and P. C. Appelbaum. 1998. Comparative activities of Clinafloxacin against gram-positive and -negative bacteria. Antimicrob. Agents Chemother. 42:1269-1273.
14. Endtz, H. P., J. W. Mouton, J. G. den Hollander, N. van den Braak, and H. A. Verbrugh. 1997. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections. Antimicrob. Agents Chemother. 41:1146-1149.
15. Ferrándiz, M. J., A. Fenoll, J. Liñares, and A. G. de la Campa. 2000. Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44: 840-847.
16. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
17. Friedland, I. R., M. Med, and G. H. McCracken, Jr. 1999. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N. Eng. J. Med. 331(6):377-382.
18. Gill, M. J., N. P. Brenwald, and R. Wise. 1999. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:187-189.
19. Gootz, I. D., R. Zaniewski, S. Haskell, B. Schmieder, J. Tankovic, D. Girard, P. Courvalin, and R. J. Polzer. 1996. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob. Agents Chemother. 40:2691-2697.
20. Hershberger, E., and M. J. Rybak. 2000. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. Antimicrob. Agents Chemother. 44:598-601.
21. Ho, P.-L., T.-L, Que, D. N.-C. Tsang, T.-K. Ng, K.-H. Chow, and W.-H. Seto. 1999. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents Chemother. 43:1310-1313.
22. Hoellman, D. B., G. Lin, M. R. Jacobs, and P. C. Appelbaum. 1999. Antipneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. J. Antimicrob. Chemother. 43:645-649.
23. Hoogkamp-Korstanje, J. A. A. 1997. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin, and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. J. Antimicrob. Chemother. 40:427-431.
24. Kaatz, G. W., S. M. Seo, and C. A. Ruble. 1993. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37:1086-1094.
25. Kanematsu, E., T. Deguchi, M. Yasuda, T. Kawamura, Y. Nishino, and Y. Kawada. 1998. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis. Antimicrob. Agents Chemother. 42:433-435.
26. Lafredo, S. C., B. D. Foleno, and K. P. Fu. 1993. Induction of resistance of Streptococcus pneumoniae to quinolones in-vitro. Chemotherapy 39:36-39.
27. Legg, J. M., and A. J. Bint. 1999. Will pneumococci put quinolones in their place? J. Antimicrob. Chemother. 44:425-427.
28. Lode, H., K. Borner, and P. Koeppe. 1998. Pharmacodynamics of fluoroquinolones. Clin. Infect. Dis. 27:33-39.
29. Lorian, V. 1996. Antibiotics in laboratory medicine. 4th ed., p. 482-483. Williams & Wilkins, Baltimore, Md.
30. Markham, P. N. 1999. Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine. Antimicrob. Agents Chemother. 43:988-989.
31. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd rd. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
32. Norrby, S. R. 1997. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment? J. Antimicrob. Chemother. 40(Suppl. A):99-101.
33. Pan, X.-S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326
34. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1995. Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin, and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J. Antimicrob. Chemother. 35:230-232.
35. Perry, C. M., J. A. Barman Balfour, and H. M. Lamb. 1999. Gatifloxacin. Drugs 58:683-696.
36. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Pharmacodynamics of levofloxacin, a new paradigm for early clinical trials. JAMA 279:125-129.
37. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467.
38. Sullivan, J. T., M. Woodruff; J. Lettieri, V. Agarwal, G. J. Krol, P. T. Leese, S. Watson, and A. H. Heller. 1999. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob. Agents Chemother. 43:2793-2797.
39. Thomas, J. K., A. Forrest, S. M. Bhavnani, J. M. Hyatt, A. Cheng, C. H. Ballow, and J. J. Schentag. 1998. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42:521-527.
40. Thornsberry, C., M. E. Jones, M. L. Hickey, Y. Mauriz, J. Kahn, and D. F. Sahm. 1999. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. J. Antimicrob. Chemother. 44:749-759.
41. Visalli, M. A., M. R. Jacobs, and P. C. Appelbaum. 1996. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenam, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 40:362-366.
42. Zeller, V., C. Janoir, M. D. Kitzis, L. Gutmann, and N. J. Moreau. 1997. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1973-1978.